Literature DB >> 24658066

Reoperation after combat-related major lower extremity amputations.

Scott M Tintle1, Scott B Shawen, Jonathan A Forsberg, Donald A Gajewski, John J Keeling, Romney C Andersen, Benjamin K Potter.   

Abstract

OBJECTIVE: Complication rates leading to reoperation after trauma-related amputations remain ill defined in the literature. We sought to identify and quantify the indications for reoperation in our combat-injured patients.
DESIGN: Retrospective review of a consecutive series of patients.
SETTING: Tertiary Military Medical Center. PATIENTS/PARTICIPANTS: Combat-wounded personnel sustaining 300 major lower extremity amputations from Operations Iraqi and Enduring Freedom from 2005 to 2009. INTERVENTION: We performed a retrospective analysis of injury and treatment-related data, complications, and revision of amputation data. Prerevision and postrevision outcome measures were identified for all patients. MAIN OUTCOME MEASUREMENTS: The primary outcome measure was the reoperation on an amputation after a previous definitive closure. Secondary outcome measures included ambulatory status, prosthesis use, medication use, and return to duty status.
RESULTS: At a mean follow-up of 23 months (interquartile range: 16-32), 156 limbs required reoperation leading to a 53% overall reoperation rate. Ninety-one limbs had 1 indication for reoperation, whereas 65 limbs had more than 1 indication for reoperation. There were a total of 261 distinct indications for reoperation leading to a total of 465 additional surgical procedures. Repeat surgery was performed semiurgently for postoperative wound infection (27%) and sterile wound dehiscence/wound breakdown (4%). Revision amputation surgery was also performed electively for persistently symptomatic residual limbs due to the following indications: symptomatic heterotopic ossification (24%), neuromas (11%), scar revision (8%), and myodesis failure (6%). Transtibial amputations were more likely than transfemoral amputations to be revised due to symptomatic neuromata (P = 0.004; odds ratio [OR] = 3.7; 95% confidence interval [95% CI] = 1.45-9.22). Knee disarticulations were less likely to require reoperation when compared with all other amputation levels (P = 0.0002; OR = 7.6; 95% CI = 2.2-21.4).
CONCLUSIONS: In our patient population, reoperation to address urgent surgical complications was consistent with previous reports on trauma-related amputations. Additionally, persistently symptomatic residual limbs were common and reoperation to address the pathology was associated with an improvement in ambulatory status and led to a decreased dependence on pain medications.

Entities:  

Mesh:

Year:  2014        PMID: 24658066     DOI: 10.1097/BOT.0b013e3182a53130

Source DB:  PubMed          Journal:  J Orthop Trauma        ISSN: 0890-5339            Impact factor:   2.512


  13 in total

1.  Challenges in definitive fracture management of blast injuries.

Authors:  Wade Gordon; Kevin Kuhn; Greg Staeheli; David Dromsky
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

2.  Risk factors and failures in the management of limb injuries in combat casualties.

Authors:  Antoine Grosset; Georges Pfister; Nicolas de l'Escalopier; Soryapong Plang; Anne-Pauline Russo; James-Charles Murison; Laurent Mathieu; Sylvain Rigal
Journal:  Int Orthop       Date:  2019-04-11       Impact factor: 3.075

3.  Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model.

Authors:  Gabriel J Pavey; Ammar T Qureshi; Donald N Hope; Rebecca L Pavlicek; Benjamin K Potter; Jonathan A Forsberg; Thomas A Davis
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

4.  Intrawound Antibiotic Powder Decreases Frequency of Deep Infection and Severity of Heterotopic Ossification in Combat Lower Extremity Amputations.

Authors:  Gabriel J Pavey; Peter M Formby; Benjamin W Hoyt; Scott C Wagner; Jonathan A Forsberg; Benjamin K Potter
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

5.  Impact of Operational Theater on Combat and Noncombat Trauma-Related Infections.

Authors:  David R Tribble; Ping Li; Tyler E Warkentien; Bradley A Lloyd; Elizabeth R Schnaubelt; Anuradha Ganesan; William Bradley; Deepak Aggarwal; M Leigh Carson; Amy C Weintrob; Clinton K Murray
Journal:  Mil Med       Date:  2016-10       Impact factor: 1.437

6.  Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.

Authors:  Gabriel J Pavey; Ammar T Qureshi; Allison M Tomasino; Cary L Honnold; Danett K Bishop; Shailesh Agarwal; Shawn Loder; Benjamin Levi; Maurizio Pacifici; Masahiro Iwamoto; Benjamin K Potter; Thomas A Davis; Jonathan A Forsberg
Journal:  Bone       Date:  2016-06-28       Impact factor: 4.398

7.  Inhibition of Mammalian Target of Rapamycin Signaling with Rapamycin Prevents Trauma-Induced Heterotopic Ossification.

Authors:  Ammar T Qureshi; Devaveena Dey; Erin M Sanders; Jonathan G Seavey; Allison M Tomasino; Kaitlyn Moss; Benjamin Wheatley; David Cholok; Shawn Loder; John Li; Benjamin Levi; Thomas A Davis
Journal:  Am J Pathol       Date:  2017-10-10       Impact factor: 4.307

8.  Epidemiology of Trauma-Related Infections among a Combat Casualty Cohort after Initial Hospitalization: The Trauma Infectious Disease Outcomes Study.

Authors:  David R Tribble; Margot R Krauss; Clinton K Murray; Tyler E Warkentien; Bradley A Lloyd; Anuradha Ganesan; Lauren Greenberg; Jiahong Xu; Ping Li; M Leigh Carson; William Bradley; Amy C Weintrob
Journal:  Surg Infect (Larchmt)       Date:  2018-05-02       Impact factor: 2.150

Review 9.  Microbiology and risk factors associated with war-related wound infections in the Middle East.

Authors:  Z T Sahli; A R Bizri; G S Abu-Sittah
Journal:  Epidemiol Infect       Date:  2016-03-02       Impact factor: 4.434

10.  Traumatic andropause after combat injury.

Authors:  Gareth Huw Jones; Jackson Kirkman-Brown; Davendra Murray Sharma; Douglas Bowley
Journal:  BMJ Case Rep       Date:  2015-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.